Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track JAZZ with free AI briefings, catalyst countdowns, and dilution alerts.

JAZZ · Jazz Pharmaceuticals plc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$2.9B Cash on Hand
CF+ Cash Runway
9.3% Short Interest
$297.5 Analyst Target (22)
Follow JAZZ by email Get an email when JAZZ reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about JAZZ, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoAOptions-implied move
2027-04-16 oral cannabidiol capsule formulation NDA 66% ±21% by Jun 17

Options-implied move = price of the at-the-money straddle for the first option expiry after the PDUFA date, as a share of the stock price (Yahoo Finance quotes, Nov 17). It prices every move until that expiry, not only the FDA decision.

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →

📣 What JAZZ Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Cannabidiol
FDA approved Jun 2018 · Epidiolex
Lennox Gastaut Syndrome Phase 4 · NCT05044819 Active not recruiting
Lurbinectedin
FDA approved Jun 2020 · Zepzelca
Small-Cell Lung Cancer Phase 3 · NCT05091567 Active not recruiting
Zanidatamab (ZW25)
FDA approved Nov 2024 · Ziihera
Gastric Neoplasms Phase 3 · NCT05152147 Active not recruiting
Asparaginase Erwinia chrysanthemi
FDA approved Jun 2021 · Rylaze
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative Phase 2 · NCT06738368 Suspended
Defibrotide
FDA approved Mar 2016 · Defitelio
Covid19 Phase 2 · NCT04652115 Recruiting
JZP258 (XYWAV) Idiopathic Hypersomnia Phase 4 · NCT05875974 Completed
Dordaviprone (ONC201) Diffuse Intrinsic Pontine Glioma Phase 3 · NCT05476939 Recruiting
JZP926 capsule Juvenile Myoclonic Epilepsy Phase 2/3 · NCT07723963 Recruiting
Fluorouracil Gastric Neoplasms Phase 3 · NCT05152147 Active not recruiting
CBD-OS Developmental and Epileptic Encephalopathy (DEE) Phase 3 · NCT07723976 Recruiting
Calcium, Magnesium, Potassium, And Sodium… Narcolepsy Phase 3 · NCT07625280 Recruiting
DRD2 Antagonist/ClpP Agonist ONC206 Meningioma Phase 2 · NCT07533942 Recruiting
Osimertinib Small Cell Lung Cancer ( SCLC ) Phase 1/2 · NCT07153055 Recruiting
MicroRNA-10b Antagomir-Iron Oxide/Dextran-based… HER2-positive Breast Cancer Phase 1/2 · NCT05868226 Recruiting
Vincristine B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative Phase 2 · NCT06738368 Suspended
Evorpacept (ALX148) HER2-positive Breast Cancer Phase 1/2 · NCT05868226 Recruiting

Also used in these trials (approved or third-party drugs, not JAZZ's own candidates): Oxaliplatin, Gemcitabine Hydrochloride, Pembrolizumab, Everolimus, Etoposide, Durvalumab, Tislelizumab, Trastuzumab, Cisplatin, Carboplatin, Capecitabine, Atezolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

JAZZ holds $2.9B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 8 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when JAZZ files for a raise →

👥 Who Owns JAZZ

Insiders 3.4% Institutions (926 holders) 96.6% Public and other holders 0%
HolderTypeShares% of sharesAs of
Blackrock Inc. Institution (13F) 6,454,463 10.06% 2026-09-30
FMR LLC Institution (13G, 5%+) 5,601,907 8.73% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 3,103,522 4.83% 2026-03-31
Vanguard Portfolio Management LLC Institution (13F) 3,071,767 4.79% 2026-09-30
Capital World Investors Institution (13F) 2,393,393 3.73% 2026-09-30
LSV Asset Management Institution (13F) 2,135,935 3.33% 2026-09-30
State Street Corporation Institution (13F) 2,067,988 3.22% 2026-09-30
Franklin Resources, Inc. Institution (13F) 1,943,969 3.03% 2026-09-30
Franklin Templeton, Inc. Institution (13F) 1,943,969 3.03% 2026-09-30
Geode Capital Management, LLC Institution (13F) 1,532,561 2.39% 2026-09-30
Dimensional Fund Advisors LP Institution (13F) 1,453,265 2.26% 2026-09-30
Seamus Mulligan
Director
Insider 1,286,254 2.00% 2026-08-05

Share count 64,189,052 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-06
filed 2026-11-10
COZADD BRUCE C
Option exercise (M) 734 $136.18 340,609
2026-11-06
filed 2026-11-10
COZADD BRUCE C
Option exercise (M) 85,766 $136.18 426,375
2026-11-06
filed 2026-11-10
COZADD BRUCE C
Sale (S) 27,714 $234.91 398,661
2026-11-06
filed 2026-11-10
COZADD BRUCE C
Sale (S) 10,688 $235.82 387,973
2026-11-06
filed 2026-11-10
COZADD BRUCE C
Sale (S) 24,483 $236.84 363,490

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-08-25 Ziihera sBLA +0.2% +2.3% —
2025-11-05 — NDA +0.2% -0.4% -0.5%
2025-10-07 — NDA +6.2% -0.2% -1.8%

Browse all historical PDUFA outcomes →

Get the full JAZZ picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for JAZZ and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.